Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive p...

por Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Publicado 2013

美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

por AZZOLI, Christopher G., JR, Sherman Baker, TEMIN, Sarah, PAO, William, ALIFF, Timothy, BRHMER, Julie, JOHNSON, David H., LASKIN, Janessa L., MASTERS, Gregory, MILTON, Daniel, NORDQUIST, Luke, PFISTER, David G., PIANTADOSI, Steven, SCHILLER, Joan H., SMITH, Reily, SMITH, Tomas J., STRWN, John R., TRENT, David, GIACCONE, Giuseppe, 丁, 燕, 南, 娟, 刘, 谦
Publicado 2010